Peptide Knowledge Base · Cosmetic
GHK-Cu (injectable): what it is, what the evidence says, and its real status
Short version
A copper peptide given by injection, a separate regulatory question from the topical cosmetic form.
Education onlyEvidence grade D · Animal and lab evidence; human trials still to come
That’s the honest answer. Everything below is the detail.
Topical GHK-Cu being legal tells you nothing about the injectable.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: No FDA category, nomination withdrawn.
How does GHK-Cu (injectable) work?
A copper-binding tripeptide studied for effects on extracellular-matrix turnover and wound-healing signaling, almost entirely in animal and cell-culture models.
What it does — and what it does not do
What it does: Studied in animals and cell culture for matrix remodeling and wound-healing signaling.
What it does not do: It is not the topical cosmetic ingredient under a different label, and Peptós.LIFE does not offer it, it is education only.
How honest is the evidence?
Evidence grade D — Animal and lab evidence; human trials still to come.
no controlled human data by any injected route; the evidence base is animal and cell-culture, and the largest controlled human topical trial found no difference from placebo
A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.
What we still don't know: There are no human pharmacokinetic data for GHK-Cu by any route. Normal copper handling is regulated at intestinal absorption and biliary excretion, so what an injected route does to copper load is a reasonable question with no published answer.
WADA status: Not prohibited by name on the 2026 List; unapproved-substance rules may still apply..
Who should not take it
Not offered. The injectable route is not eligible for compounding under the 503A bulks pathway and sits outside FDA's enforcement-discretion policy. FDA's stated concern for this route is immunogenicity from aggregation and peptide-related impurities, with limited human data to inform safety.
Sources
FDA, bulk drug substances nominated for use in compounding under 503A (content current 05/14/2026) · FDA Category 2, nominated-but-withdrawn table · FDA Pharmacy Compounding Advisory Committee, next-meeting agenda · Bishop, tripeptide-copper for venous stasis ulcers, J Vasc Surg 1992 · Barut, intralesional multi-ingredient scalp series, J Clin Aesthet Dermatol 2018 · Pickart & Margolina, GHK-Cu regenerative actions
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.
Embed this card on your site · free, CC BY 4.0, no key.
Last reviewed · Peptós.LIFE · Not medical advice.
Cite this page
GHK-Cu (injectable). Peptós.LIFE Peptide Knowledge Base. Reviewed Aug 16, 2026. https://peptos.life/peptides/ghk-cu-injectable
Free to reuse under CC BY 4.0, with attribution and a link. Machine-readable: JSON · CSV · what is in the export.